The FDA is approving Cephelin for its prevention and treatment of COVID-19.
Cephalon, which is also known as Zidovudine, is a prescription drug for the treatment of people with severe COVID, including COVID/H7N1 coronavirus.
The FDA is moving forward with its decision to approve Cepherin for its treatment of severe COVI-19 as the virus has been moving slowly across the U.S.
The new approval comes after the FDA made several changes to the approval process in the last few months, and it’s one of the first times the agency has made changes to a prescription medication approved for use in the United States.
The drug is already on the market and has been approved by several states, but the FDA is now changing how it will review approval requests.
Previously, the agency was able to only approve the drug if it met a few criteria.
Those criteria included being approved by the FDA for the prevention of COVI and showing a clear reduction in COVID transmission.
That means a drug that had been approved for the first time in one state would be approved in all states.
Now, the FDA will be reviewing all applications submitted by the U,S.
government to the FDA to approve the drugs for the U.,S.
market.
And that means that applications submitted from more than one state could be rejected.
In order to receive approval, a drug has to meet the criteria for approval in each state.
The criteria include a reduction in transmission of COV-2 and a reduction of the disease burden, among other things.
According to the National Institute of Allergy and Infectious Diseases, COVID cases have been falling across the country, and the number of Americans being treated for the virus is on the rise.
The numbers of Americans treated for COVID have been on the decline since last summer.
In fact, more than 20 million people have been treated with COVID medications, according to the CDC.
However, a new study shows that the number in the U.-S.
who are taking COVID drugs is growing.
In the first half of 2018, the number that took the medications in the first six months of the year dropped by 13 percent, according the Centers for Disease Control and Prevention.
That’s according to data from the U-M Health System.
The study also found that the average time to treat a COVID drug prescription dropped by almost 10 minutes.
In 2018, more Americans were getting the drugs than they were getting flu shots.
